GlaxoSmithKline Says FDA Accepts SNDA Application for Zejula

Date : 02/24/2020 @ 2:56PM
Source : Dow Jones News
Stock : Glaxosmithkline Plc (GSK)
Quote : 1472.4  -27.0 (-1.80%) @ 2:36PM

GlaxoSmithKline Says FDA Accepts SNDA Application for Zejula

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

2 Months : From Feb 2020 to Apr 2020

Click Here for more Glaxosmithkline Charts.

By Michael Dabaie

 

GlaxoSmithKline PLC said the U.S. Food and Drug Administration accepted the company's submission of a supplemental New Drug Application for Zejula as a maintenance treatment in the first-line setting for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.

The FDA is reviewing the sNDA under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure treatments are available to patients as early as possible.

GlaxoSmithKline said the application is supported by data from the Prima study, which demonstrated clinically-meaningful outcomes of niraparib treatment in the first-line maintenance setting.

Zejula is currently approved in the U.S. as a maintenance treatment for women with recurrent ovarian cancer who are in response to platinum-based chemotherapy regardless of BRCA mutation status. It is also approved as a treatment for women with advanced ovarian cancer, following three or more chemotherapy regimens.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

February 24, 2020 09:41 ET (14:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.